Want to see AIMD full AI Analyst Report?
Top Page
Ainos
(NASDAQ:AIMD)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▲(5.63% Upside)
Action:Reiterated
Date:09/29/26
Overall score is driven primarily by very weak financial performance (minimal/declining revenue, large losses, and ongoing cash burn) alongside increased balance-sheet risk from sharply lower equity and higher leverage. Technicals also detract, with the stock trading below key moving averages and bearish momentum indicators. Valuation is not supportive because the negative P/E reflects lack of profitability and no dividend yield is available.
Positive Factors
Partner-funded VELDONA licensing
The VELDONA structure can reduce Ainos’ future development funding burden while preserving platform ownership and potential royalty participation. Partner-funded clinical and regulatory execution also lets Ainos direct capital and management attention toward its Chemical Intelligence strategy.
Negative Factors
Very weak operating performance
The current revenue scale is far below the cost base, and recurring losses show that commercialization has not yet produced sustainable operating economics. Without materially stronger revenue or cost improvement, profitability and the ability to reinvest in growth remain constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
Partner-funded VELDONA licensing
The VELDONA structure can reduce Ainos’ future development funding burden while preserving platform ownership and potential royalty participation. Partner-funded clinical and regulatory execution also lets Ainos direct capital and management attention toward its Chemical Intelligence strategy.
Read all positive factors
Ainos (AIMD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$9.60M
Dividend YieldN/A
Average Volume (3M)240.57K
Price to Earnings (P/E)―
Beta (1Y)2.12
Revenue Growth-87.73%
EPS Growth51.12%
CountryUS
Employees41
SectorTechnology
Sector Strength88
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.52
Shares Outstanding7,384,073
10 Day Avg. Volume670,157
30 Day Avg. Volume240,568
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.93
Price to Sales (P/S)56.41
P/FCF Ratio-1.51
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Ainos Business Overview & Revenue Model
Company Description
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, ...
Ainos Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
22
Negative
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.60K | 124.16K | 20.73K | 122.11K | 3.52M | 594.56K |
| Gross Profit | -4.76M | -4.68M | -31.87K | -253.73K | 1.41M | 410.38K |
| EBITDA | -8.96M | -9.28M | -9.44M | -8.77M | -9.14M | -1.83M |
| Net Income | -14.45M | -14.77M | -14.86M | -13.77M | -14.01M | -3.89M |
Balance Sheet | ||||||
| Total Assets | 19.56M | 20.87M | 28.82M | 31.84M | 37.11M | 40.82M |
| Cash, Cash Equivalents and Short-Term Investments | 1.42M | 417.35K | 3.89M | 1.89M | 1.85M | 1.75M |
| Total Debt | 13.81M | 11.00M | 12.00M | 5.96M | 1.27M | 3.62M |
| Total Liabilities | 16.28M | 13.31M | 13.30M | 7.39M | 2.48M | 30.63M |
| Stockholders Equity | 3.28M | 7.56M | 15.52M | 24.45M | 34.63M | 10.20M |
Cash Flow | ||||||
| Free Cash Flow | -4.49M | -4.65M | -5.83M | -4.79M | -3.67M | -1.39M |
| Operating Cash Flow | -4.47M | -4.61M | -5.81M | -4.69M | -3.04M | -1.25M |
| Investing Cash Flow | 23.12K | -2.22K | -125.29K | -101.53K | -630.18K | -180.52K |
| Financing Cash Flow | 4.70M | 1.01M | 8.03M | 4.92M | 3.85M | 3.15M |
Ainos Technical Analysis
Negative
1.42
Price Trends
1.42
Negative
1.66
Negative
1.69
Negative
Market Momentum
-0.04
Positive
45.52
Neutral
32.32
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIMD, the sentiment is Negative. The current price of 1.42 is above the 20-day moving average (MA) of 1.40, above the 50-day MA of 1.42, and below the 200-day MA of 1.69, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 45.52 is Neutral, neither overbought nor oversold. The STOCH value of 32.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIMD.
Ainos Risk Analysis
Ainos disclosed 52 risk factors in its most recent earnings report. Ainos reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Expansion into industrial and other non-healthcare environments may expose AI Nose to new and unforeseen risks. Q4, 2025
2.
We rely on the availability of licenses to third-party technology that may be difficult to replace or that may cause errors or delay implementation of our software and services should we not be able to continue or obtain a commercially reasonable license to such technology. Q4, 2025
3.
Our reliance on third-party components and cloud infrastructure could disrupt AI Nose operations, and any errors, disruption, performance problems, or failure in their or our operational infrastructure could adversely affect our business, financial condition, and results of operations. Q4, 2025
Ainos Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
46 Neutral | $8.02M | -0.21 | -536.78% | ― | ― | 22.10% | |
45 Neutral | $12.72M | -1.37 | -47.22% | ― | -91.94% | 55.29% | |
44 Neutral | $9.60M | -0.54 | -217.50% | ― | -87.73% | 51.12% | |
42 Neutral | $7.92M | -0.29 | -181.02% | ― | ― | 66.94% | |
42 Neutral | $9.42M | -1.40 | -70.81% | ― | ― | 56.99% |
* Technology Sector Average
AIMD
Ainos
1.35
-2.18
-61.67%
BLRX
Bioline RX Ltd Sponsored ADR
2.37
-1.63
-40.75%
SNGX
Soligenix
0.37
-1.02
-73.55%
CMMB
Chemomab Therapeutics
1.43
-1.29
-47.43%
FBLG
FibroBiologics, Inc.
1.24
-9.74
-88.71%
Ainos Corporate Events
Business Operations and Strategy
Ainos Licenses VELDONA Platform, Shifts Focus to Chemical Intelligence
Positive
Sep 28, 2026
On September 24, 2026, Ainos granted Taiwan-based BioPhoenix a global, exclusive and sublicensable license to develop and commercialize its VELDONA oral interferon alpha technology for Sjögren’s disease and thrombocytopenia, with Ainos ...
Business Operations and StrategyPrivate Placements and Financing
Ainos Secures Short-Term Unsecured Credit Facility in Taiwan
Positive
Jul 9, 2026
On July 3, 2026, Ainos, Inc. entered into a General Agreement for Omnibus Credit Lines with CTBC Bank Co., Ltd. in Taiwan, securing a short-term unsecured credit facility of NT$62,000,000, or about US$1.94 million, at an annual interest rate of 2....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.